18 Stocks Moving In Thursday's Pre-Market Session

Gainers

• PhotoMedex Inc PHMD rose 52.2 percent to $1.75 in pre-market trading after ICTV Brands, Inc agreed to acquire the consumer products business of PhotoMedex for $9.5 million.
• Jaguar Animal Health Inc JAGX rose 31.9 percent to $1.51 in pre-market trading after the company entered into an agreement for a potential merger with Napo Pharmaceuticals, Inc.
• SCYNEXIS Inc SCYX rose 21 percent to $5.81 in pre-market trading after the company disclosed that results from Phase 2 studies confirmed antifungal activity of oral SCY-078 in patients with Candida infections. The company also reported closing of a $15 million term loan with Solar Capital Ltd. SLRC.
• Aurinia Pharmaceuticals Inc AUPH rose 19.5 percent to $4.84 in pre-market trading after the company disclosed 24-week data from the AURION study.
• Alliqua Biomedical Inc ALQA rose 19.1 percent to $1.000 in the pre-market trading. Alliqua BioMedical agreed to acquire Soluble Systems, LLC for $35 million and reported preliminary Q3 revenue of $4.85 million.
• Zumiez Inc. ZUMZ rose 15 percent to $21.00 in pre-market trading. Zumiez reported an 11.5 percent rise in its Septmber sales and raised its Q3 revenue guidance.
• Kamada Ltd KMDA rose 11.8 percent to $5.70 in pre-market trading after the company reported the extension of GLASSIA supply and distribution deal with Shire.
• PTC Therapeutics, Inc. PTCT rose 7.4 percent to $14.72 in pre-market trading after gaining 2.85 percent on Wednesday.
• Mizuho Financial Group Inc. (ADR) MFG rose 4.2 percent to $3.49 in the pre-market trading session after gaining 0.30 percent on Wednesday.
• JD.Com Inc(ADR) JD shares rose 2.6 percent to $28.65 in pre-market trading. Wal Mart increased stake in JD.com to 10.8 percent.

Find out what's going on in today's market and bring any questions you have to Benzinga's PreMarket Prep.

Losers

• Alnylam Pharmaceuticals, Inc. ALNY shares fell 43.2 percent to $39.95 in pre-market trading after the company disclosed that it has decided to discontinue the Revusiran development. Leerink Swann downgrades Alnylam Pharmaceuticals from Outperform to Market Perform and lowered the price target from $107.00 to $40.00, while Barclays also downgraded the stock from Overweight to Equal-weight and lowered the price target from $85.00 to $50.00.
• Twitter Inc TWTR shares fell 16 percent to $20.90 in pre-market trading. Alphabet Inc GOOGL and its Google are the latest to drop out as interested parties to a possible takeover of the company. "Google does not currently plan to make a bid for Twitter," according to Recode's Kara Swisher and Kurt Wagner.
• Idera Pharmaceuticals Inc IDRA shares fell around 12.6 percent to $2.28 in pre-market trading as the company announced plans to offer $50 million shares common stock.
• The Medicines Company MDCO shares fell 10.5 percent to $34.45 in pre-market trading. The Medicines Company issued a progress update on its ongoing ORION-1 study of PCSK9si.
• Resources Connection, Inc. RECN fell 6.5 percent to $14.00 in pre-market trading despite a revenue beat. While Q1 sales of $143.39 million beat estimates by $860,000, EPS of $0.15 fell $0.02 short of expectations. Also impacting on shares was the unexpected retirement of CEO Anthony Cherbak; the company cited health considerations, and said he would be replaced by Kate Duchene until a permanent CEO is found.
• Summit Therapeutics PLC (ADR) SMMT shares fell 5.6 percent to $13.55 in pre-market trading.
• Arrowhead Pharmaceuticals Inc ARWR shares fell 3.6 percent to $7.25 in pre-market trading following Alnylam Pharmaceuticals news.
• Tesla Motors Inc TSLA fell 2.7 percent to $202.80 in pre-market trading. Goldman Sachs downgraded Tesla from Buy to Neutral and lowered the price target from $240.00 to $185.00.